Meiwu Falls on Shenzhen Hookup
Shares in China-based Meiwu Technology Company Limited (NASDAQ: WNW) were in the red Tuesday, on word the company entered into an agreement with Shenzhen Zhinuo Weichuang Technology Co., Ltd., to enhance the Company’s brand influence and market competitiveness.Zhinuo Weichuang, based in Guangdong China, primarily engages in the research, development, and sale of technology products in the fields of smart technology, AI-driven finance, and the internet, as well as the provision of intelligent services and investment-related activities. The company engaged Zhinuo Weichuang for its comprehensive marketing services for a term from July 1, 2025 to June 30, 2026.Through its resources across the entire internet, Zhinuo Weichuang aims to increase the Company’s brand exposure, strengthen market competitiveness, and enhance the brand’s premium. Leveraging digital marketing technologies and channel networks, Zhinuo Weichuang plans to assist the Company in the analysis of active user data, display data, and browsing behavior across both user and brand-facing channels. This approach will enable more precise targeting and performance insights for the Company’s products. Zhinuo Weichuang also aims to help expand the Company’s market reach across both domestic and international dimensions.This morning’s news release states the parties have agreed on a comprehensive service and fee structure. WNW shares dipped four cents, or 2.4%, to open Tuesday at $1.62.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


